Whereas in the past a negative diagnostic 131 I whole body scan (WBS) was interpreted as the lack of significant residual or recurrent thyroid cancer, today the patient with negative WBS and measurable serum thyroglobulin (Tg) presents a diagnostic and therapeutic dilemma. Previous studies have shown a high rate of visualization of uptake and a decrease in Tg after one or more therapeutic doses of 131 I. In order to further assess the significance of this finding, retrospective analysis of patients with persistent thyroglobulinemia and negative WBS was performed for evidence of surgically amenable disease. Seven out of seventeen patients had neck ultrasound and/or computerized tomography (neck Ϯ chest) showing the presence of pathologically confirmed malignant masses ranging from 1 to 4 cm in size. Their serum Tg while on L-thyroxine ranged between 2.4 and 1173 pmol/l. Removal of the identified masses resulted in a greater than 75% reduction in serum Tg in four out of five patients in the group. One patient achieved a serum Tg of < 1.5 pmol/l while hypothyroid. Empiric 131 I treatment of eleven patients with persistent thyroglobulinemia resulted in demonstrated uptake on post-therapy scan in seven. Further study is needed to compare the efficacy, safety and cost of a diagnostic approach to radiologically identify and surgically resect identified disease versus empiric therapeutic 131 I treatment and high-dose WBS in this group of patients. Patients with negative WBS and persistent thyroglobulinemia, even to levels < 4.5 pmol/l, may have significant foci of thyroid cancer in surgically accessible areas. This suggests the need for a redefinition or clarification of the term 'recurrence' in thyroid cancer.
Introduction
The follow-up of previously thyroidectomized and 131 Itreated patients with well-differentiated thyroid cancer routinely includes thyroglobulin (Tg) determination as well as diagnostic whole body 131 I scan (WBS) (1, 2) . Radioiodine is administered therapeutically when uptake is demonstrated on WBS. For those with negative diagnostic WBSs and measurable serum Tg a diagnostic and treatment dilemma ensues. In the absence of anti-Tg autoantibodies which might falsely elevate or decrease the result (3), the presence of Tg in a patient who has been treated with total thyroid ablation indicates the continued presence of thyroid tissue, suggesting recurrence of persistent thyroid cancer. Three options for approaching these patients exist: (i) to wait a defined interval followed by 131 I treatment only if and when the diagnostic WBS is positive, (ii) administration of therapeutic doses of 131 I for both treatment and performing a highly sensitive 131 I WBS and (iii) search for and resection of surgically amenable disease.
Several reports show that empiric 131 I treatment has demonstrable effects in patients with negative diagnostic WBSs but measurable serum Tg (4) (5) (6) (7) (8) . Although numerous reports have described alternate imaging procedures for the follow-up of thyroid cancer patients (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , few have assessed the response to therapeutic intervention based on the findings from these images (23) .
We performed a retrospective analysis to answer the following two questions. (i) In the unique group of patients with negative WBS but persistent thyroglobulinemia and in the environment of common clinical practice, does neck ultrasound (US) or neck/chest computerized tomography (CT) localize significant sites of thyroid cancer? (ii) How much does surgical intervention of identified disease change the level of thyroglobulinemia? pathology reports, all previous imaging studies and all treatments. All verifiable studies or treatments were included, even if they were not performed at this institution. Persistent thyroglobulinemia was defined as a Tg of > 4.5 pmol/l while either hypothyroid or on L-thyroxine (L-T 4 ) treatment in a patient who has previously been treated with the equivalent of subtotal, near total or total thyroidectomy (as defined by the operating surgeon) followed by radioiodine administration (to ablate residual thyroid or treat cancer) and who does not have readily identifiable disease by one or more subsequent WBSs within 4 years prior to the Tg determination. Four years was an arbitrary cut-off based on the available data. Patients who had thyroid lobectomy Ϯ isthmusectomy followed by 131 I ablation were not included.
Serum Tg was compared before and after surgery in one patient (no. 21) who did not fulfill the strict criteria for persistent thyroglobulinemia with negative WBS (at the time of surgery) as defined above.
Methods
The data were analyzed to compare the diagnostic efficacy of neck US and neck/chest CT (or magnetic resonance imaging (MRI)) in identifying surgically amenable disease as well as to assess the therapeutic response to surgical removal of identified disease or empiric 131 I treatment. Response was assessed by comparing pre-and post-therapy Tg concentrations while on and/or off L-T 4 and by pre-and posttherapy imaging, where available. Statistical analysis was by analysis of variance or chi square, where appropriate.
All Tg measurements, except where otherwise noted, were by RIA (Endocrinology Laboratory at the University of Southern California, Los Angeles, CA, USA). The assay has a sensitivity of 1.5 pmol/l and a normal, nonathyreotic range of 7.6-76 pmol/l. Tg autoantibodies were measured on all samples at the time of Tg determination. Where other laboratory performance sites were used, the Tg persistence and Tg autoantibody level (by RIA) could be verified by measurement of at least one sample/patient at the University of Southern California (normal < 1 U/ ml). To convert from pmol/l to ng/ml multiply Tg by 0.659.
US and CT were not performed under controlled conditions and the sensitivity of the methods may have improved over the years of the study. Not all CTs were performed using iodinated contrast or with uniform section cuts.
Ethics
This study was approved by the Institutional Review Board of the University of Pittsburgh Medical Center.
Results

Characteristics of patients with persistent thyroglobulinemia
Twenty-one patients fulfilled the study inclusion criteria (Table 1) . They were 35 Ϯ 16 (meanϮS.D.) years at diagnosis. Four were Յ20 years old. There were twelve females and nine males. The extent of initial operation ranged from subtotal thyroidectomy to total thyroidectomy accomplished in one or more procedures. All except one had papillary carcinoma of the thyroid (PCT). Lymph node removal, performed only if suspected of cancer involvement, identified lymph node metastases in 48%. Thirty-three percent had capsular or vascular invasion. None had distant metastases at diagnosis. The initial 131 I dose was 119 Ϯ 42 mCi. In the context of past negative WBS, 17 of the patients with persistent thyroglobulinemia had additional imaging studies aimed at localizing or following previously unidentified disease. This included 19 neck USs, 17 neck and/or chest CTs, two MRIs, and seven thallium scans (Tables 2 and 3) . One patient had four USs, two patients had two USs, three had two CTs and one had three CTs. At the time of study inclusion, patient 16 had known recurrent disease in the superior mediastinum (which was not discovered in the context of a negative WBS). CT studies that were performed in patient 16 are not reported in the analysis.
Findings in surgically treated patients
US or CT discovered suspicious masses measuring between 1 and 4 cm, prompting surgical intervention in seven patients. Serum Tg in this group ranged between 2.4 and 1173 pmol/l while on L-T 4 suppression ( Table 2 ). The initial study was not always positive. Six USs were negative in three patients prior to the final positive study. Earlier USs missed significant disease in two patients. In patient 2, a non-palpable 4 cm neck mass was found after three previous yearly USs showed < 1 cm masses. In patient 4, neck US was negative only 1 month prior to a second study, performed in the same institution, showing a 3 cm mass. This falsely negative US was due to lack of imaging lateral to the internal jugular veins. The requirement for consistent expert technique aimed at identifying cervical adenopathy is one reason CT may be superior to US in the average practice setting. In addition, CT may detect mediastinal disease that cannot be seen on neck US (patient 3). Patient 6, with a remote history of pulmonary tuberculosis, had both neck nodules (later proven to be thyroid cancer) and multiple pulmonary nodules which did not visualize with subsequent high-dose 131 I treatment (Table 4) . Two patients from this group had positive thallium uptake of masses identified by US or CT.
The Tg response to ten operations in eight patients, including the seven patients listed in Table 2 , is shown in Table 5 . Seven operations in six patients resulted in a decreased serum Tg. In most cases, this is demonstrated by comparing the Tg on L-T 4 before surgery with that after surgery. In all patients except three, the operation was performed by a single endocrine surgeon. Selective lymphadenectomy was performed in seven operations and modified radical neck dissection in two (patients 5 and 4, second operation). Patient 2 was operated upon at another institution and patient 3 had mediastinoscopy with excision of an involved mediastinal lymph node. None had complications from the surgical procedure. Patient 3 achieved a negative post-therapy 131 I WBS and follow-up Tg < 1.5 pmol/l both on and off L-T 4 . Patient 1 had a lower Tg while hypothyroid after surgery than while on L-T 4 before surgery. Patient 4 had no Tg response to the removal of two of ten lymph nodes containing PCT but had a 66% Tg decrease to modified radical neck dissection 1 year later. In patients 6 and 7 insufficient data are available to draw conclusions on surgical response. Patient 21 (Tables 1 and 5 ) was operated upon within the first year after the initial 131 I treatment of thyroid cancer. In two separate surgical procedures her serum Tg decreased from 142 to 15 pmol/l and then from 15 to < 1.5 pmol/l while on L-T 4 . Despite this, she subsequently had persistent thyroglobulinemia of 20 pmol/l in association with a negative WBS while hypothyroid.
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Patients with persistent thyroglobulinemia and negative imaging
Ten of seventeen patients with persistent thyroglobulinemia and negative WBS did not go to surgery on the basis of CT or US findings (Table 3) . Their characteristics at presentation (age, tumor size, multicentricity, lymph node involvement and invasion) were not different from those later proven to have recurrent cancer. Their mean Tg was lower (10 Ϯ 3.2 on L-T 4 and 123 Ϯ 86 while off L-T 4 ) but this was not statistically significant. US and CT findings, if present, were of uncertain significance in several cases, prompting further evaluation, patient anxiety and expense.
There are two possible explanations for the persistent thyroglobulinemia in this group. First, the malignancy could have been in a location that was not imaged or could not be visualized by the techniques employed (18) . This group was not studied as completely as the operated group. Only 40% were evaluated by both US and CT (and CT was not always of both neck and chest). Tg is a sensitive marker and may be detectable even if tumor masses are small and not shown by neck US or CT scan. Other imaging techniques may have localized cancer masses or even demonstrated suspicious foci within normal-appearing lymph nodes. Though characteristics have been described for benign versus malignant lymph nodes these criteria were not used (24) . In addition, fine needle aspiration biopsy of lymph nodes was not attempted (25) (26) (27) .
Second, the measured Tg (by RIA) may have been falsely elevated due to Tg autoantibody (3) in three patients. Each displayed little or no Tg response to thyrotrophin (TSH) stimulation (Table 3) . Two had pulmonary nodules. In patient 8, follow-up showed resolution, while in patient 13 the nodules increased in size, suggesting they may indeed represent thyroid cancer despite lack of uptake on high dose 131 I scan. Patient 20, who had no abnormalities on CT, had undetectable Tg by IRMA. Such discrepant Tg results by RIA and IRMA, especially in patients with Tg autoantibodies, have been reported but do not reliably exclude the presence of metastatic thyroid cancer (28) . In fact, the mere persistence of Tg autoantibodies may suggest the persistence of thyroid cancer (29) (30) (31) .
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Response to therapeutic
I administration
Over a period of years, both empiric high dose 131 I and surgical removal of identified masses were used in the treatment of certain patients (nos 1, 2, 4, 6 and 7) while others were treated with 131 I alone ( NP, not performed. * Empiric 131 I prior to subsequent surgery; ** surgery prior to empiric 131 I; *** surgery both prior to and following empiric 131 I; † known bulky mediastinal recurrence; ‡ known negative CT and US prior to empiric therapy; § surgery 2 weeks prior to laboratory determination. k Measured by Nichols assay (< 39 nmol/l). Table 5 Tg responses to surgery. TSH and Tg values over time (from left to right) are shown. Tg is reported in pmol/l; TSH in mU/l.
After surgery
Before surgery
On NP, not performed. Patient also received therapeutic 131 I * 3 months, ** 5 months, *** 11 months and **** 10 months before Tg determination; † no negative WBS before surgery. 131 I despite no visualization of uptake on post-therapy scan. There were insufficient data on the others to assess their Tg response to 131 I or to compare the population as a whole to those who were surgically treated. It should be noted that this 131 I-treated thyroglobulinemic population may not be equivalent to a previously reported population where several patients ultimately achieved a Tg of < 7.6 pmol/l in response to one or more therapeutic 131 I doses. Specifically, the baseline Tg while hypothyroid in the previously reported population was 108 Ϯ 50 pmol/l, and if the three patients with Tg values over 152 pmol/l are excluded, the population baseline Tg was only 22 ng/ml (4). In contrast, five patients from our population had Tg in excess of 455 pmol/l when hypothyroid.
Discussion
Serum Tg measurement is increasingly recognized as an important test in the follow-up of patients with welldifferentiated thyroid cancer (15, (32) (33) (34) (35) . We define persistent thyroglobulinemia as measurable serum Tg in a patient who has had surgical thyroidectomy followed by radioiodine treatment to ablate or treat residual thyroid cancer. Since Tg is increased by TSH stimulation, Tg sensitivity is greater during induced hypothyroidism than while on L-T 4 treatment (5, 8, 12, (36) (37) (38) (39) (40) . Most well-differentiated thyroid cancers display concordance between 131 I uptake (or WBS) and serum Tg. However, the high sensitivity of serum Tg may now predict a lack of complete treatment response in a group of patients who have negative diagnositc WBSs. Indeed, we now demonstrate that 35% of a population of thyroid cancer patients with negative diagnostic WBSs and persistent thyroglobulinemia had surgically proven metastatic deposits of thyroid cancer that could be demonstrated by US and/or CT of the neck and chest.
The finding of surgically accessible disease in this patient population is not surprising. Previous reports on similar patients have shown visualization of uptake on post-therapy scans in surgically accessible sites, including the thyroid bed, cervical lymph nodes or mediastinum (4, 16) . Likewise, in other groups of thyroid cancer patients, imaging with thallium, US or MRI has also localized disease to these areas (11-13, 16, 18, 20, 23, 41) . The Tg response to surgical intervention of such identified disease has not been previously reported and may be surprising. In four of five patients, a > 75% decrease in Tg occurred in response to initial surgical excision of identified masses. One had no Tg response to either selective lymphadenectomy or high-dose 131 I but had a 66% decrease in Tg following a second more extensive operation.
Since not all patients had both studies, we cannot compare the efficacy of US and CT in detecting significant disease. However, the results suggest that the detection of recurrent or metastatic disease by CT or US will depend on the expertise available at a given institution. Based on the higher technical dependence of US, in average clinical practice CT may be superior and should include high-resolution study of both the neck and chest. This is important to demonstrate the lack of widely metastatic thyroid cancer, obviating the expected response to surgical intervention, and to identify all sites of isolated foci to ensure completeness of the operation for masses that are surgically accessible.
It has been suggested that isolated focal metastatic deposits of thyroid cancer should be surgically resected before treatment with radioiodine (42) . Several cases reported here support this recommendation. Alternatively, visualization of uptake on post-therapy WBSs may aid in establishing potential target areas for future surgical intervention.
The independent significance of persistent thyroglobulinemia on recurrence or mortality from thyroid cancer, either with positive or negative WBS, is unknown. In patients with known metastases from thyroid cancer, a Tg greater than 15 pmol/l on L-T 4 treatment and a negative WBS has been associated with a poor prognosis (34) . However, improved survival in patients with 'complete remission' (as defined by resolution of metastatic uptake on 131 I scans following one or more therapeutic 131 I doses) has been found in association with still measurable Tg while hypothyroid (43) . In the absence of the study inclusion history of persistent thyroglobulinemia, the timing of presentation and the size of the masses that were demonstrated (Table 2 ) are consistent with significant cancer 'recurrence', or the clinical diagnosis of apparent disease at a time removed from the inital treatment. Yet, these patients were included for study based on persistent thyroglobulinemia and negative diagnostic WBSs, suggesting that persistent thyroglobulinemia may predict 'recurrence'. Cancer 'recurrence' has been associated with increased morbidity and mortality in PCT (44, 45) . The site of such recurrence is often in thyroid bed or cervical lymph nodes (44, 46, 47) , as was demonstrated here.
In conclusion, patients with negative WBS and persistent thyroglobulinemia, even to levels < 4.5 pmol/l using a sensitive RIA, may have significant foci of thyroid cancer in surgically accessible areas. Removal of these foci may result in substantial decrements in serum Tg, including complete resolution. Further study is needed to compare the efficacy and safety of this approach to one or more doses of empiric 131 I. The term cancer 'recurrence' is a misnomer in light of sensitive Tg assays which can document that many, if not all, thyroid-ablated patients with persistent thyroglobulinemia have cancer persistence with progression to clinical diagnosis of 'recurrence' at a later date. While further scientific validation is still required, it could be speculated that an unmeasurable serum Tg (by RIA) while hypothyroid prospectively identifies patients who have absolute eradication of tumor, or are 'cured'.
